Investment Comparison: Spyre Therapeutics vs. argenex on Nasdaq
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Spyre Therapeutics and argenex, both healthcare companies listed on Nasdaq, are currently being compared for investment. The comparison examines factors including analyst recommendations, valuation, earnings, profitability, and institutional ownership. Spyre Therapeutics has a consensus target price of $110.40, while argenex has a consensus target price of $1,158.76.
From themarketsdaily.com
Why it matters
argenex reports higher revenue and earnings than Spyre Therapeutics. However, Spyre Therapeutics is trading at a lower price-to-earnings ratio, indicating it is currently more affordable. Analysts suggest argenex is more favorable due to its higher possible upside.
From themarketsdaily.com
Who's involved
- NasdaqStock exchange where the companies are listed
- CellectisBiopharmaceutical company being compared
- Cronos Group IncCompany being compared
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange